# Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma

> **NCT00717522** · PHASE2 · TERMINATED · sponsor: **Celgene** · enrollment: 7 (actual)

## Conditions studied

- Soft Tissue Sarcoma

## Interventions

- **DRUG:** Pomalidomide

## Key facts

- **NCT ID:** NCT00717522
- **Lead sponsor:** Celgene
- **Sponsor class:** INDUSTRY
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2008-08-01
- **Primary completion:** 2009-01-01
- **Final completion:** 2009-01-01
- **Target enrollment:** 7 (ACTUAL)
- **Why stopped:** Study enrollment was terminated due to a corporate strategic decision unrelated to patient safety.
- **Last updated:** 2019-11-19


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT00717522

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT00717522, "Efficacy and Safety Study of CC-4047 (Pomalidomide) to Treat Advanced Soft Tissue Sarcoma". Retrieved via AI Analytics 2026-06-23 from https://api.ai-analytics.org/clinical/NCT00717522. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*